Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2022-11-16 Regulatory Filings
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
Offering Prospectus (ENG) (FINAL) (INCLUDING E-DISCLAIMER).pdf
Regulatory Filings Classification · 98% confidence The document is a detailed legal notice and prospectus related to a 'RIGHTS OFFERING' and 'COMPREHENSIVE RECAPITALIZATION' involving the issuance of new ordinary shares and preferential rights. It explicitly mentions the document is a 'prospectus' and details the terms of a public offering, subscription periods, and listing on Euronext Brussels. This content strongly aligns with documents related to capital structure changes, fundraising, and the formal offering of securities, which falls under the 'Capital/Financing Update' category (CAP). While it is a prospectus, which is a comprehensive document, the core subject matter is the capital raising event itself, making CAP the most specific fit among the provided options, rather than a general Annual Report (10-K) or an Interim Report (IR). It is not a simple announcement of a report (RPA) because it contains the full terms and conditions of the offering.
2022-11-16 English
Offering Prospectus (DUT) (FINAL) (INCLUDING E-DISCLAIMER).pdf
Capital/Financing Update Classification · 98% confidence The document is a lengthy prospectus written in Dutch, detailing a public offering to existing shareholders via rights issue ('Aandelenuitgifte met Voorkeurrecht') and a private placement ('Private Plaatsing van de Scrips') for Biocartis Group NV. It explicitly mentions the issuance of new ordinary shares ('nieuwe gewone aandelen') at a specific price (€ 0,75 per aandeel) and the admission to listing on Euronext Brussels. The text discusses capital structure changes ('herkapitalisatie') involving convertible bonds and debt-for-equity swaps. This structure—a detailed document outlining the terms of a security offering, including rights issues and private placements, intended for regulatory approval and investor information—is characteristic of a prospectus related to a capital raising event. This aligns best with the 'Capital/Financing Update' (CAP) category, as it is the primary document detailing the financing transaction, rather than just a brief announcement (RPA/ER). Since it is a comprehensive document detailing the terms of the offering, it is classified as CAP.
2022-11-16 Dutch
221116 Rights Offering - Launch PR (ENG) - FINAL.pdf
Capital/Financing Update Classification · 99% confidence The document is a press release dated November 16, 2022, announcing the launch of a 'rights offering' involving the issuance of new ordinary shares at a specific price to existing shareholders. This action directly relates to the company's capital structure, fundraising, and financing activities. Keywords like 'rights offering,' 'issuance of up to 33,476,932 offered shares,' 'EUR 25,107,699.00,' 'recapitalization transactions,' and 'raise new capital' strongly indicate a capital/financing event. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific corporate finance action.
2022-11-16 English
221116 Rights Offering - Launch PR (DUT) - FINAL.pdf
Capital/Financing Update Classification · 98% confidence The document is explicitly titled as a 'PERSBERICHT VOORKENNIS / GEREGLEMENTEERDE INFORMATIE' (Press Release Advance Notice / Regulated Information) dated November 16, 2022. The core subject is the launch of a 'aandelenuitgifte met voorkeurrecht' (rights issue) amounting to EUR 25.1 million by issuing new ordinary shares. This clearly indicates a corporate action related to raising capital and changing the capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves shares, the primary focus is the financing transaction itself, not a general share issue announcement (SHA) or a transaction in own shares (POS), as it is a primary issuance tied to a specific rights offering structure.
2022-11-16 Dutch
EGM Minutes_20221114.pdf
AGM Information Classification · 98% confidence The document text explicitly mentions the holding of an 'buitengewone algemene vergadering' (Extraordinary General Meeting) for 'BIOCARTIS GROUP' on November 14, 2022. The agenda items listed include proposals regarding capital increases ('Kapitaalverhoging'), changes to convertible bonds, and statutory amendments. The structure, the presence of a bureau (chairman, secretary), attendance lists, and the detailed agenda strongly indicate this is the official record or minutes of a shareholder meeting where significant corporate actions were decided upon. Since the document details the proceedings and resolutions of a general meeting, the most appropriate classification is AGM-R (AGM Information), as this category covers presentations and materials shared during the Annual General Meeting (and by extension, Extraordinary General Meetings, which deal with similar high-level corporate governance matters). Although it is a record of the meeting rather than a presentation, it falls under the scope of meeting materials.
2022-11-14 Dutch
221114 PR EGM 2 Outcome_ENG_FINAL.pdf
AGM Information Classification · 99% confidence The document is titled "Results of the Extraordinary Shareholders' Meeting held on 14 November 2022" and discusses the approval of remaining agenda items from a previous meeting, which is directly related to shareholder voting and corporate governance actions. This strongly aligns with the definition of AGM Information (AGM-R) or potentially Declaration of Voting Results & Voting Rights Announcements (DVA). Since it explicitly reports the results of a general shareholders' meeting (an Extraordinary General Shareholders' Meeting), DVA is the most precise fit, as it covers official results from shareholder votes. The document is a press release announcing these results, not the formal minutes or proxy materials themselves, but the core content is the voting outcome.
2022-11-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.